Regulatory perspective in safety and efficacy of new drug approval
- At: 2011 FIP Congress in Hyderabad (India)
- Type: Presentation
- By: KAMBOJ, Rajender (Lupin Ltd., Pune, India)
New drug development process is becoming increasingly tougher. R&D timelines & costs are consistently rising. Adding to this challenge, drugs are getting withdrawn from the market & there is a growing expectation of all stakeholders from regulatory authorities to approve safer drugs. Like never before, the drug development and approval process.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.